Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Analysis of Diabetic Retinopathy, Glaucoma and Macular Degeneration Diagnosis Via Digital Fundus Images With Artificial Intelligence

Authors not listed

Retinow Health Technologies and R&D Industry Joint Stock Company · 2023

Abstract

Eye diseases are a major public health problem worldwide and one of the main causes of vision loss. Diseases such as diabetic retinopathy, glaucoma and macular degeneration in particular can lead to serious vision loss and negatively affect quality of life. Early diagnosis of these diseases, determination of appropriate treatment methods and protection of patients' quality of life are of great importance. In recent years, artificial intelligence (AI) technologies have offered great opportunities for disease diagnosis and management in the medical field. Artificial intelligence algorithms developed for retinal image analysis have become an effective tool in the early diagnosis of eye diseases such as diabetic retinopathy, glaucoma and macular degeneration. Ophthalmic imaging and scanning systems supported by AI technology facilitate the diagnosis of these diseases and contribute to the treatment processes. Artificial intelligence can provide an effective solution for automatic diagnosis of this disease and prediction of disease progression. Retinow AI was developed to accelerate early diagnosis of these three important eye diseases (diabetic retinopathy, glaucoma, macular degeneration), increase access and reduce costs. This software aims to provide a solution to the shortage of ophthalmologists and the limitations of existing methods. Retinow AI's ability to diagnose these diseases with high sensitivity and accuracy through fundus photographs is being evaluated within the scope of clinical research. According to the hypothesis, the software's accuracy rate can reach 90%, thus speeding up clinical processes and reducing the workload of healthcare personnel. In addition, it is planned to be used as an effective screening tool in regions where ophthalmologists are insufficient.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-09 MST

Cite this

APA
Anonymous. (2023). Analysis of Diabetic Retinopathy, Glaucoma and Macular Degeneration Diagnosis Via Digital Fundus Images With Artificial Intelligence. <em>Retinow Health Technologies and R&D Industry Joint Stock Company</em>. https://clinicaltrials.gov/study/NCT06645964
Vancouver
Anonymous. Analysis of Diabetic Retinopathy, Glaucoma and Macular Degeneration Diagnosis Via Digital Fundus Images With Artificial Intelligence. Retinow Health Technologies and R&D Industry Joint Stock Company. 2023.
BibTeX
@misc{anon2023Analys, title = {Analysis of Diabetic Retinopathy, Glaucoma and Macular Degeneration Diagnosis Via Digital Fundus Images With Artificial Intelligence}, author = {Anonymous}, journal = {Retinow Health Technologies and R&D Industry Joint Stock Company}, year = {2023}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings